Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2023 · 10-Q
Revenue$5.34M$5.34M+12,604.8% vs Q3 2022 Net Income-$45.02M-$45.02MN/M vs Q3 2022 EPS Diluted-$0.55-$0.55N/M vs Q3 2022 Operating Income-$50,163,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$35,698,000N/M Margins · derivedOperating margin-940.1%+136012.3 pt vs Q3 2022
Net margin-843.7%+131837.3 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 3, 2023 · 34 d after period end